Live price temporarily unavailable.
Tempus AI (TEM) is a Health Care company in the Russell 1000. Latest news and coverage below.
Tempus AI revenue & net income history (FY2022–FY2025)
| FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $320.7M | $531.8M | $693.4M | $1.27B |
| Growth (year over year) | — | +65.8% | +30.4% | +83.4% |
| Operating income | −$265.4M | −$196.1M | −$691.1M | −$252.9M |
| Operating margin | −82.8% | −36.9% | −99.7% | −19.9% |
| Net income | −$289.8M | −$214.1M | −$705.8M | −$245.0M |
| Net margin | −90.4% | −40.3% | −101.8% | −19.3% |
| EPS (diluted) | −$5.30 | −$4.20 | −$6.23 | −$1.41 |
| Balance sheet | ||||
| Cash and equivalents | $302.9M | $165.8M | $341.0M | $604.8M |
| Total assets | — | $564.1M | $926.1M | $2.27B |
| Total liabilities | — | $840.7M | $869.8M | $1.78B |
| Shareholders' equity | −$1.13B | −$1.38B | $56.3M | $491.3M |
| Cash flow | ||||
| Operating cash flow | −$168.2M | −$214.3M | −$189.0M | −$218.1M |
| Capital expenditure | $18.4M | $34.6M | $22.1M | $21.0M |
| Free cash flow | −$186.6M | −$248.9M | −$211.2M | −$239.1M |
| Dividends paid | $5.63M | $5.63M | $5.63M | $0 |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $180.9M | $200.7M | $255.7M | $314.6M | $334.2M | $367.2M | $348.1M | $382.5M |
| Growth (year over year) | +33.0% | +35.8% | +75.4% | +89.6% | +84.7% | +83.0% | +36.1% | +21.6% |
| Operating income | −$53.6M | −$50.7M | −$68.7M | −$61.8M | −$61.0M | −$61.4M | −$84.7M | −$75.9M |
| Operating margin | −29.6% | −25.3% | −26.9% | −19.6% | −18.3% | −16.7% | −24.3% | −19.8% |
| Net income | −$75.8M | −$13.0M | −$68.0M | −$42.8M | −$80.0M | −$54.2M | −$125.9M | $5.64M |
| Net margin | −41.9% | −6.5% | −26.6% | −13.6% | −23.9% | −14.8% | −36.2% | 1.5% |
| EPS (diluted) | −$0.46 | $2.56 | −$0.40 | −$0.25 | −$0.46 | −$0.30 | −$0.71 | $0.03 |
| Balance sheet | ||||||||
| Cash and equivalents | $388.0M | $341.0M | $151.6M | $186.3M | $655.9M | $604.8M | $521.2M | $599.6M |
| Total assets | $971.7M | $926.1M | $1.54B | $1.63B | $2.28B | $2.27B | $2.14B | $2.37B |
| Total liabilities | $918.0M | $869.8M | $1.22B | $1.32B | $1.77B | $1.78B | $1.72B | $1.92B |
| Shareholders' equity | $53.7M | $56.3M | $326.2M | $309.6M | $507.8M | $491.3M | $416.4M | $444.9M |
| Cash flow | ||||||||
| Operating cash flow | $48.7M | −$39.3M | −$105.6M | $44.2M | −$119.8M | −$36.8M | −$73.3M | −$7.53M |
| Capital expenditure | $43.0K | $7.96M | $2.07M | $7.51M | $6.71M | $4.75M | $8.20M | $6.13M |
| Free cash flow | $48.6M | −$47.2M | −$107.7M | $36.6M | −$126.5M | −$41.5M | −$81.5M | −$13.7M |
| Dividends paid | $0 | $0 | — | — | $0 | $0 | — | — |
From Tempus AI's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Tempus AI
Tempus AI, Inc. is an American health technology company founded in 2015 by Eric Lefkofsky in Chicago, Illinois. It was established by Lefkofsky soon after his wife was diagnosed with breast cancer. Tempus uses data and artificial intelligence (AI) to create precision medicine services, including diagnostics, for oncology, cardiology, radiology, and depression. The company went public on the Nasdaq on June 14, 2024, under the ticker symbol "TEM."
- Headquarters
- Chicago, Illinois From SEC filings, Oct 2026
Recent News
No recent news mentioning Tempus AI in our feed yet.
Other Health Care companies to compare with TEM
- TCRX TScan Therapeutics
- TDOC Teladoc Health Inc
- TECX Tectonic Therapeutic Inc
- TELA TELA Bio
- TENX Tenax Therapeutics
- TFX Teleflex
- TGTX Tg Therapeutics Inc
- THC Tenet Healthcare